SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

MORE HEADLINES

» Markets | Economy | Companies

- Home Prices Sank Further In Most Parts of US in 3rd Quarter

PHARMA'S MARKET VIDEO

» More

Making The Vaccine 06 Nov 2009
Inside the big push to get enough H1N1 vaccines, with CNBC's Mike Huckman.
Making the Flu Vaccine 06 Nov 2009
Wayne Pisano, CEO of Sanofi-Pasteur, discusses the making of the flu vaccine with CNBC's Mike Huckman.

Flu Fighting: On the Frontlines

06 Nov 2009

Flu vaccines were once a business that many drug companies avoided, but that segment of the pharma industry is now firmly in the spotlight. CNBC's Mike Huckman visits the only injectable flu vaccine plant in the US for a behind-the-scenes look.

Under the Flu Vaccine Veil

06 Nov 2009

J&J to Cut Up to 8,000 Jobs 03 Nov 2009
Johnson & Johnson says it will eliminate 6-7 percent of its workforce in a cost-cutting move. CNBC's Mike Huckman has the details.
J&J Announces Massive Restructuring 03 Nov 2009
Johnson & Johnson has announced a restructuring and that it will cut 6-7 percent of its global workforce. CNBC's Mike Huckman has the latest details.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

Aug.18

2:33 PM ET

Monday, 18 Aug 2008

AstraZeneca Gives FluMist A Shot In The Arm

Posted By:Mike Huckman

Topics:Stock Market | Medicine | Corporate News | Mergers & Acquisitions | Pharmaceuticals

Sectors:Health Care Equipment and Services | Health Care | Pharmaceuticals

Companies:ASTRAZENECA PLC | ImClone Systems Inc. | Eli Lilly and Company | Amylin Pharmaceuticals | Bristol-Myers Squibb Co

Ads for flu vaccines have traditionally been confined to public service announcements (PSAs), health and media alerts.

So, that's why I was surprised to see this colorful full-page ad in The New York Times this weekend for FluMist from AstraZeneca/MedImmune.

Flumist Advertisement
NY Times
Flumist Advertisement

FluMist, as its name might suggest, is the vaccine that gets sprayed in your nose. MedImmune developed the product and brought it to market. But by industry standards, it's been a mediocre seller: For example, during the last flu season, FluMist had $55 million in revenue. That's a drop in the bucket for AstraZeneca [AZN Loading... () ].

That's probably why AZN, which bought MedImmune but let the company keep its name, is trying to put some big pharma marketing muscle behind FluMist. It's just kinda strange to see a big ad for a flu vaccine, especially in the middle of summer -- although I assume it's designed to blend in with and capitalize on the back-to-school shopping season stuff.

The companies recently announced that they started shipping around 12 million doses for the upcoming season, and that FluMist will be available in more locations than ever before. A FluMist spokesperson says this is a limited-time print-ad campaign that started running in the The Wall Street Journal and the Times within the past couple weeks.

MedImmune is one of the biopharma companies that billionaire activist investor Carl Icahn took a stake in, and saw it through to a very lucrative takeover by AZN.

This weekend Barron's ran a piece regarding something I've been reporting on and blogging about for quite some time: big pharma's continuing thirst for biotech. The article mentions Icahn's ImClone Systems [IMCL Loading... () ] and the "uncertain" outcome of Bristol-Myers Squibb's [BMY Loading... () ] offer for IMCL.

The story also ticks off the short-list of potential biotech takeover targets, including another one of Icahn's new babies: Amylin Pharmaceuticals [AMLN Loading... () ].

The story couldn't save Amylin shares from dropping more than 8 percent Monday, however, on reports that the FDA is seeking stronger warnings about the risk of pancreatitis in patients taking the firm's injectable diabetes drug Byetta.

In a note to subscribers today, David Kliff, editor of "The Diabetic Investor" newsletter, points out that Icahn recently increased his stake in AMLN from 6.3 million to 6.8 million shares.

Kliff says, "Carl sees the path for Amylin and has the clout to hit Lilly [LLY Loading... () ] (AMLN's diabetes drug partner)...with a baseball bat pushing Lilly to acquire Amylin."

For the record, LLY and AMLN officials have consistently said they're happy with the partnership as it is. But while Kliff praises Icahn for his AMLN strategy, he also expresses incredulity about Icahn's new stake in another diabetes player, Emisphere [EMIS Loading... () ]. Diabetes drug goliath Novo Nordisk [NVO Loading... () ] recently did a deal with EMIS to develop an oral treatment for the disease.